Details of the Drug

General Information of Drug (ID: DMVVU4V)

Drug Name

SLN360

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidemia	5C80.Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

RNA interference

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apolipoprotein A messenger RNA (LPA mRNA)	TTU9LGY	APOA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05537571) A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events. U.S.National Institutes of Health.
2	Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308.